Market Size (2016)
2016
$49.74B
Vertical: HealthcareBase Year: 201811 Sections
Market Size (2016)
2016
$49.74B
Projected (2024)
2024
$92.41B
CAGR (2016–2024)
8.0%
8.0%Key Players
113+
This report covers Cholic Acid Market with forecasts from 2016 to 2024. 113 key companies are profiled.
The Cholic Acid Market market is projected to grow at a CAGR of 8.0% from 2016 to 2024.
Historical performance and future projections (2020–2030, USD Billion)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMarket Size (USD Mn)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansCholic acid is a primary bile acid synthesized by the liver from cholesterol. The role of bile acids is to emulsify (breakdown into small particles) fats and thus promote the process of digestion. Cholic acid is primarily used as an intermediate for the production of ursodeoxycholic acid (UDCA), which is an active pharmaceutical ingredient (API) used for various indications like the dissolution of gall stones and treating and preventing liver diseases.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThis report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.
Base Year
2018
Historical Period
2016 – 2018
Forecast Period
2018 – 2024
Primary Interviews
150+
Historical data (2016–2018) and forecast period (2018–2024)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThreat of New Entrants
The threat of new entrants is medium in the global cholic acid market. In Porter’s Five Forces Analysis, the ‘Threat of New Entrants’ refers to the threat that new competitors pose to existing competitors in an industry. A profitable industry will attract more competitors looking to achieve profits. As the number of entrants increases, the profitability of the present players in the industry subsequently decreases. The global cholic acid market has a medium threat of new entrants, threatening the existing players.
Bargaining Power of Suppliers
Bargaining power of suppliers in the global cholic acid market is medium. The bargaining power of suppliers estimates how easy it is for the suppliers to influence the prices of the final products made by innovators. Businesses must obtain the necessary resources that they need from the resource suppliers to carry out their activities.
In the global cholic acid industry, the number of suppliers is comparatively less than the number of firms operating in the sector, and only a few of them have a large hold on the cholic acid market. The recessionary pressures have reduced the price of many components and raw materials due to downward demand trends. Moreover, the switching cost of these suppliers is also medium as the suppliers tend to enter long-term associations with the manufacturers.
1.1.3 Threat of Substitutes
The threat of substitutes in the global cholic acid market is medium to low. The substitute to the cholic acid can only be in the form of large molecules. Buyer propensity to substitute is low due to the lesser availability of substitutes in this market. In addition, the high degree of switching cost minimizes the threat of substitutes.
Bargaining Power of Buyers
The bargaining power of the buyer is considered to have a low impact on the industry. The bargaining power of the buyers evaluates how easy it is for the buyers to affect the price of pharmaceutical products. There is a low number of players with capabilities to manufacture high-end drugs.
Also, the high differential advantage of the cholic acid market coupled with low or poor existing substitutes for high tech products makes the position of the manufacturers strong.
Intensity of Rivalry
The degree of competition in the global cholic acid market is high. The moderate degree of product differentiation among existing players increases the intensity of rivalry in the market. The intensity of competitive rivalry evaluates the capability and the level of rivalry among competitors in the market. It also refers to the extent to which firms within an industry put pressure on one another and limit each other’s profit potential. Rivalry among industry players can affect industry profits through downward pressure on prices, increased innovation, increased advertising, and increased service/product improvements, among others.
Market estimates by geography (2024)
InsightEurope leads with $35.14B by 2024, while Americas is projected to grow fastest at a 8.6% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2016 | 2018 | 2024 | CAGR | SHARE |
|---|---|---|---|---|---|
| Asia Pacific | $14.98B | $20.78B | $28.50B | 8.4% | 31% |
| Europe | $19.88B | $26.59B | $35.14B | 7.4% | 38% |
| Middle East and Africa | $1.17B | $1.61B | $2.19B | 8.1% | 2% |
| Americas | $13.72B | $19.20B | $26.58B | 8.6% | 29% |
| Total | $49.74B | $68.18B | $92.41B | 8.0% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.

Analytical insights on Cholic Acid Market covering market dynamics, competitive landscape, and strategic outlook.
The Cholic Acid Market market is projected to reach $92.41B by 2024, growing at 8.0% CAGR.
Gallstones are deposits of cholesterol and other digestive fluids that form in the gallbladder. Cholic acid is used as an active pharmaceutical ingredient in manufacturing medications for dissolution of gallstones. Apart from treating gallstones, cholic acid is also used in treating bile acid synthesis disorders and Zellweger Spectrum Disorders.
According to the American Cancer Society, gallstones are one of the major factors contributing to gallbladder cancer. The cases of gallbladder cancer diagnosed are increasing globally. For instance, according to a study by the World Cancer Research Fund (WCRF) International, around 2,20,000 new cases of gallbladder cancer were diagnosed globally in the year 2018.
This increase in the cases of gallbladder cancer reflects the probable increase in the increased prevalence of one of its factors, bile stones. Owing to this increase, the demand for cholic acid, which is used as an active pharmaceutical ingredient (API), is expected to increase and thus boost the global cholic acid market growth.
The European region is leading the manufacturing of cholic acid globally followed by the Americas and Asia-Pacific. The drug manufacturers in the Middle Eastern and African region mainly rely on import for meeting their requirement of cholic acid. Around 80% of the cholic acid is manufactured in other regions of the world, and only 20% is manufactured in the Middle East and Africa. This provides an opportunity for manufacturers to establish new manufacturing facilities for cholic acid.
The exporters of cholic acid are abiding by the good manufacturing practice (GMP) in the European region, whereas the FDA is regulating the quality assurance in the US and other regions. The regulatory compliance is considered to be the primary hurdle challenging the cholic acid (API) market at every point.
Besides, the Indian cholic acid manufacturers are investing to comply with the US FDA regulations for obtaining contracts from the US-based companies. They are also filing the drug master file (DMF) applications in the US. Thus, it has been observed that Indian cholic acid manufacturers are strengthening their presence in the global cholic acid market. Although these regulations are serving to improve and maintain the quality of drugs, they are also curbing the growth of the cholic acid (API) manufacturing market, especially in developing regions of Asia-Pacific.
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 113 companies operating in the Cholic Acid Market market, including revenue, employee count, and market positioning where available.
Showing 113 of 113 companies
Zhejiang Yongning Pharmaceutical
Company Headquarters: Taizhou, Zhejiang Founded: 1974 Company Working: Zhejiang Yongning Pharmaceutical is a pharmaceutical company that is engaged in manufacturing and marketing of a wide range of innovative medicines and pharmaceutical APIs in China. It is one of the national high-tech companies in the Zhejiang province. It develops and sells antibiotic drugs, respiratory drugs, cardiovascular drugs, vitamin tablets, health care drugs, and other related products.
Showa Denko KK
Company Headquarters: Tokyo, Japan Founded: 1939 Workforce: ~10,476 Company Working: Showa Denko KK is a chemical company that engages in the manufacturing and marketing of a wide range of petrochemicals, chemicals, electronics, inorganic chemicals, aluminum, and other products. The company, along with its affiliates and subsidiaries, operates in North America, Europe, and Asia. It provides products and services that are useful and exceed customer expectation.
PharmaZell GmbH
Company Headquarters: Germany Founded: 1947 Workforce: ~800 Company Working: PharmaZell GmbH develops and manufactures APIs for pharmaceutical purposes. It provides services for the development of formulations and other pharmaceutical intermediates and produces amino acids. The company markets its products worldwide.
Panjin Hengchanglong Pharmaceutical
Company Headquarters: China Founded: 1984 Workforce: ~260 Company Working: Panjin Hengchanglong Pharmaceutical is located in China. It offers 25 major pharmaceutical products and more than 100 kinds of traditional Chinese medicinal foods. The company is primarily involved in manufacturing tablets; hard capsules; pills such as water-honeyed pills and concentrated pills; APIs; tea-containing products; and herbal tea.
New Zealand Pharmaceuticals Limited
Company Headquarters: Palmerston North, New Zealand Founded: 1971 Workforce: ~250 Company Working: New Zealand Pharmaceuticals Limited, manufactures pharmaceutical ingredients and diagnostic products for pharmaceutical and biotechnology companies. The company extracts and purifies biochemicals from the by-products of the New Zealand meat processing industry. It is one of the major manufacturers and suppliers of pharmaceutical products in the market. It also manufactures pharmaceutical ingredients, pharmaceutical intermediates, microbiological media, fermentation ingredients, dietary supplements, and cosmetic ingredients.
Kinsy SL
Company Headquarters: Alhama de Murcia, Murcia, Spain Founded: 1991 Workforce: ~200 Company Working: Kinsy SL is an independent chemical company headquartered in Spain. The company has a strong emphasis on the development and manufacturing of key APIs under the CGMP guidelines and manufacturing fine chemicals. The company’s primary focus is the development and synthesis of fine chemicals and pharmaceutical intermediates.
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Cholic Acid Market